Novo Nordisk A/S
DEEURNovo Nordisk A/S (US:NONOF) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
- Novo Nordisk A/S — NOVO-B · CO DK Registratienummer onbekend
Over het Bedrijf
- Website
- novonordisk.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- BAGSVAERD DENMARK, Denmark
- CEO
- Maziar Mike Doustdar
- Werknemers
- 66 700
- Uitstaande Aandelen
- 3.34 mld.
- Free Float
- 3.17 mld.
- Marktkapitalisatie
- 150.93 mld. EUR
- Insiders
- 5.27%
- Institutionele Beleggers
- 33.78%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- ZRPO
- ISIN
- DK0060534915
- LEI
- 549300DAQ1CVT6CXN342
- Uitkeringsratio
- 50.5%
- FCF
- 59.0 mld. DKK
- Uitkering / FCF
- 88%
- Schuld
- 143 mld. DKK2.0 jr FCF
- Dividendreeks
- 24 jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 31.12.2025 (het laatste rapport van het bedrijf).
Beschrijving
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Dividenden
Novo Nordisk A/S (NONOF) keert twee keer per jaar dividend uit. Per jaar (12 maanden tot en met de laatst aangekondigde betaling): 11.7 DKK per aandeel (betalingen: 2). Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 15.02.2027. Ononderbroken dividendgeschiedenis: 24 jaar.
| Ex-Datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-17 | 2026-08-18 | 3.7500 DKK | 1.2/3.9 % | halfjaarlijks | US:NONOF |
| 2026-03-30 | 2026-03-31 | 7.9500 DKK | 3.4/5.0 % | halfjaarlijks | US:NONOF |
| 2025-08-18 | 2025-08-19 | 3.7500 DKK | 1.1/3.4 % | halfjaarlijks | US:NONOF |
| 2025-03-31 | 2025-04-01 | 7.9000 DKK | 1.7/2.5 % | halfjaarlijks | US:NONOF |
| 2024-08-16 | 2024-08-19 | 3.5000 DKK | 1.4/3.8 % | halfjaarlijks | US:NONOF |
| 2024-03-22 | 2024-03-26 | 6.4000 DKK | 2.5/≈4.9 % | halfjaarlijks | US:NONOF |
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.38% | 46.88 mln. | 2026-07-31 |
| EuroPacific Growth Fund-… | 1.07% | 36.2 mln. | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.92% | 31.13 mln. | 2026-06-30 |
| Capital World Growth & I… | 0.77% | 26.02 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.71% | 24.13 mln. | 2026-08-31 |
| Income Fund of America | 0.52% | 17.78 mln. | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.39% | 13.1 mln. | 2026-06-30 |
| Fidelity Concord Street… | 0.37% | 12.52 mln. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 11.48 mln. | 2026-08-31 |
| Capital Income Builder | 0.3% | 10.32 mln. | 2026-07-31 |
| Cygnus Capital Advisors,… | 0% | 78 800 | 2026-06-30 |
| Generali Investments Cee… | 0% | 27 399 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 24 410 | 2026-06-30 |
| Atlas Capital Advisors I… | 0% | 5 218 | 2026-06-30 |
| Novo Holdings | — | — | — |
| Novo Nordisk Foundation | — | — | — |
